This study is recruiting. It focuses on depression and currently lists participation information in Australia, Czech Republic, Germany, Greece, Ireland, Poland, the United Kingdom, and the United States.
This study is testing whether CYB003, compared with placebo, is safe and helpful as an add-on treatment for people with depression. Participants receive CYB003 or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including UAB Psychiatry and Behavioral Neurology in Birmingham, Lighthouse Psychiatry in Gilbert, and Pillar Clinical Research - Little Rock. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Australia.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring behavioral or lifestyle intervention for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
This study is sponsored by Cybin IRL Limited. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve behavioral or lifestyle intervention, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.